Abstract:Objective To establish a method to investigate whether flow cytometry detection of minimal residual disease(MRD) in bone marrow(BM) could predict prognosis and clinically guide the risk-adjusted therapy for neuroblastoma(NB) patients. Methods Human TGW NB cell line was used to detect the immunophenotype of NB cells by flow cytometry (FCM). The FCM sensitivity of the cocktail of CD45~ FITC /CD81~ PE /CD56~ PECy5+ was tested in our lab. The results of MRD with FCM were used to evaluate neuroblastoma metastasis in BM at diagnosis and during chemotherapy.Results The TGW cell line expressed CD56 and CD81 antigen and did not express CD45. The FCM sensitivity in our lab was 1/10~ 4 .②In 144 samples from 61 patients, NB cells were found in 23 of them morphologically(BM smear). All of those 23 samples were CD45~-/ CD81~+/ CD56~+ positive by FCM. Thirty-nine BM samples were cytologically negative by BM smear but CD45~-/ CD81~+/ CD56~+ positive by FCM. There was statistically significant difference between the two methods (P﹤0.01). ③ BM samples from 31 patients were positive for neuroblastoma by FCM at diagnosis, eleven of them became negative after average 4 courses of chemotherapy. All of those 11 patients remained alive without evidence of disease (median23mos,range8-38 months). In contrast, twenty patients whose BM samples were still positive, when they received the same chemotherapy, eleven of them were relapsed and 1 patient was died of disease(median17.5 months,range6-48 months). There was statistically significant difference in disease-free survival between the two groups(P﹤0.01).④MRD in BM was tested by FCM before PBSC harvest for 19 advanced neuroblastoma patients. Fourtheen was negative, two of them were relapsed. Eleven patients remained alive without evidence of disease (median 9 months after transplant,range 4-30 months). In contrast, other 5 patients whose BM remained positive before PBSC harvest, all of them were relapsed(median 10.5months after transplant,range 1-21 months). There was a statistically significant difference in disease-free survival after transplant between the two groups(P﹤0.05).Conclusions The method for detecting micrometastasis of NB in BM or peripheral blood using FCM was high sensitive and specific. It could evaluate the response of treatment by monitoring the MRD of BM. Positive NB MRD in BM during therapy was an unfavourable factor of prognosis.

Detection of NMB - R Gene in Peripherical Blood Micro - Metastases of Patients with Small Cell Lung Cancer and Its Application

RRM1 Gene Expression in Peripheral Blood is Predictive of Shorter Survival in Chinese Patients with Advanced Non-Small-cell Lung Cancer Treated by Gemcitabine and Platinum

Prognostic Value of Microrna-10B Overexpression in Peripheral Blood Mononuclear Cells of Nonsmall-Cell Lung Cancer Patients

Detection of Micrometastases of Lung Cancer by Using Lunx Mrna Specific Reverse Transcription-Polymerase Chain Reaction

Detection of Mrna Expression of CK-19 and MUC1 Gene for Diagnosis of Lymph Node Micrometastasis in NSCLC Patients by Reverse Transcriptase-Polymerase Chain Reaction

[Detection of CK19 and CEA mRNA expression for the diagnosis of peripheral blood micrometastases in patients with non-small cell lung cancer].

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Molecuar Detection of MUC1-positive Cells in Peripheral Blood of Patients with Non-Small-cell Lung Cancer

Identification of miRNA Biomarkers for Non-small Cell Lung Cancer using Microarray Datasets and Bioinformatics Analysis

Glycoprotein Nonmetastatic B As a Prognostic Indicator in Small Cell Lung Cancer.

Detection Of Neuroblastoma Cells In Blood By Reverse Transcriptase Polymerase Chain Reaction

GPNMB Expression Associates with Inferior Prognosis in Patients with Small Cell Lung Cancer

The MiR-17-92 Gene Cluster is a Blood-Based Marker for Cancer Detection in Non-Small-Cell Lung Cancer

Combination Detection of Three Gene Markers Expressed in Circulating Cancer Cells of Non-Small Cell Lung Cancer

Midkine mRNA level in peripheral blood mononuclear cells is a novel biomarker for primary non-small cell lung cancer: a prospective study

Detection of SBEM-mRNA level in peripheral blood of patients with breast cancer and its clinical significance

Detection of Micrometastases of Non-small Cell Lung Cancer by Using CK19 mRNA and LUNX mRNASpecific Reverse Transcription-polymerase Chain Reaction

Expression of Profile of MUC1 mRNA in Lymph Node from Patients with Non-small Cell Lung Carcinoma Detected and Its Clinical Significance

The Detection of Minimal Residual Disease with Flow Cytometry and the Relationship Between Prognosis and Minimal Residual Disease in Bone Marrow in Advanced Neuroblastoma

Detection of Micrometastases in Peripheral Blood of Non-Small Cell Lung Cancer with a Refined Immunomagnetic Nanoparticle Enrichment Assay

Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer